Translational Study Using Human Abdominal Adipose Tissue Biopsies to Investigate the Role of Cannabinoid Receptor 1 (CB1) in Controlling Endocannabinoid and Adipokine Secretion

Recruiting N/A Interventional Study
Diabete Type 2 Abdominal Obesity
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Male
Study type
Interventional
Purpose
Other
Participants needed
45 (estimated)
Sponsor
Centre Hospitalier Universitaire Dijon · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Abdominal obesity and type 2 diabetes are associated with the hyperactivation of the endocannabinoid system. Several animal and human studies indicate that circulating endocannabinoid (EC) levels are correlated with body fat. Thus, adipose tissue, which possesses the enzymatic machinery for the synthesis of ECs, could be the main producer of plasma ECs. Today, it is clearly established that stimu…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Controls: * men or post-menopausal women aged between 18 and 80 * gave oral consent * to undergo visceral surgery Non-diabetic obese subjects: * men or post-menopausal women aged between 18 and 80 * BMI \> 30 * gave oral consent * to undergo visceral surgery Obese diabetic …
Contacts

Pablo ORTEGA DEBALLON

03.80.29.37.47

pablo.ortega-deballon@chu-dijon.fr

CONTACT